From lab to bedside: emerging clinical applications of thymosin alpha 1.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing clinical applications without systematic review methodology
PubMed 19392576 · doi:10.1517/14712590902911412
What was done
This narrative review summarizes established clinical indications and emerging trial applications of thymosin alpha 1, a synthetic biological response modifier, across infectious diseases, oncology, and critical care.
What was found
No quantitative data or numerical outcomes are reported in the abstract. Thymosin alpha 1 is described as approved in over 35 countries for hepatitis B and C and as an immune stimulant or adjuvant, with late-stage clinical evaluation in stage IV melanoma and hepatitis C. Emerging trial reports indicate applications in septic shock, acute respiratory distress syndrome, peritonitis, acute cytomegalovirus infection, tuberculosis, severe acute respiratory syndrome, lung infections in critically ill patients, and chemoprotection during chemotherapy.
Why it matters
The review outlines the expanding therapeutic scope of thymosin alpha 1 from chronic viral hepatitis into acute critical illness, severe respiratory infections, and oncologic supportive care.
Limits
The abstract provides no primary data, patient counts, or quantitative outcome measures. As a narrative review, it does not detail systematic search methods, study selection criteria, or formal risk-of-bias assessments for the cited trials.
Cited by
- supports In several countries outside the US, thymosin alpha-1 is approved as an adjuvant treatment for hepatitis B, hepatitis C, and specific cancers.